Persistence of virological benefits following directly administered antiretroviral therapy among drug users: Results from a randomized controlled trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 2, 2009, Pages 176-181

  Maru, Duncan Smith Rohrberg ^a,b   Bruce, Robert Douglas ^a   Walton, Mary ^a   Springer, Sandra A ^a   Altice, Frederick L ^a,c  

^a Department of Internal Medicine Section of Infectious Diseases AIDS Program   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Adherence; AIDS; Directly administered antiretroviral therapy; Directly observed therapy; HIV; Social support; Substance abuse

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIRECTLY ADMINISTERED ANTIRETROVIRAL THERAPY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOCIAL SUPPORT; TREATMENT DURATION; TREATMENT OUTCOME; ADDICTION; BLOOD; DIRECTLY OBSERVED THERAPY; DRUG EFFECT; DRUG SELF ADMINISTRATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; PATIENT COMPLIANCE; PHYSIOLOGY; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIRECTLY OBSERVED THERAPY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RNA, VIRAL; SELF ADMINISTRATION; SOCIAL SUPPORT; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 60749096015     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181938e7e     Document Type: Article

References (35)

1. Conway B, Prasad J, Reynolds R, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis. 2004;38:S402-S408.
2. Lucas GM, Weidle PJ, Hader S, et al. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin Infect Dis. 2004;38:S409-S413.
3. Mitty JA, Macalino GE, Bazerman LB, et al. The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. J Acquir Immune Defic Syndr. 2005;39:545-550.
4. Behforouz HL, Kalmus A, Scherz CS, et al. Directly observed therapy for HIV antiretroviral therapy in an urban US setting. J Acquir Immune Defic Syndr. 2004;36:642-645.
5. Tinoco I, Giron-Gonzalez JA, Gonzalez-Gonzalez MT, et al. Efficacy of directly observed treatment of HIV infection: experience in AIDS welfare homes. Eur J Clin Microbiol Infect Dis. 2004;23:331-335.
6. Greenberg B, Berkman A, Thomas R, et al. Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report. J Urban Health. 1999;76:468-480.
7. Altice FL, Maru DS, Bruce RD, et al. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45:770-778.
8. Macalino GE, Hogan JW, Mitty JA, et al. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS. 2007;21:1473-1477.
9. Maru DSR, Kozal MJ, Bruce RD, et al. Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial. J Acquir Immune Defic Syndr. 2007;46:555-563.
10. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547-549.
11. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15:1707-1715.
12. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16:767-774.
13. Lucas GM, Griswold M, Gebo KA, et al. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol. 2006;163:412-420.
14. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251-259.
15. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377-381.
16. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-347.
17. Lucas GM, Mullen BA, Weidle PJ, et al. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis. 2006;42:1628-1635.
18. Altice FL, Smith-Rohrberg D, Bruce RD, et al. Superiority of directly administered antiretroviral therapy compared to self-administered therapy among HIV-infected drug users: a randomized, controlled trial. Clin Infect Dis. 2007;45:770-778.
19. Smith-Rohrberg D, Mezger J, Walton M, et al. Impact of enhanced services on virologie outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users. J Acquir Immune Defic Syndr. 2006;43:S48-S53.
20. Smith-Rohrberg Maru D, Kozal MJ, Springer SA, et al. Directly administered antiretroviral therapy for HIV-infected drug users does not impact antiretroviral resistance: results from a randomized, controlled trial. J Acquir Immune Defic Syndr. 2007;46:555-563.
21. Maru DS, Bruce RD, Walton M, et al. Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Behav. 2007;12:284-293.
22. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42:200-209.
23. Puccio JA, Belzer M, Olson J, et al. The use of cell phone reminder calls for assisting HIV-infected adolescents and young adults to adhere to highly active antiretroviral therapy: a pilot study. AIDS Patient Care STDS. 2006;20:438-444.
24. Morin SF, Chesney MA, Ehrhardt AA, et al. Effects of a behavioral intervention to reduce risk of transmission among people living with HIV: the healthy living project randomized controlled study. J Acquir Immune Defic Syndr. 2007;44:213-221.
25. Sorensen JL, Haug NA, Delucchi KL, et al. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend. 2007;88:54-63.
26. Mitty JA, Huang D, Loewenthal HG, et al. Modified directly observed therapy: sustained self-reported adherence and HIV health status. AIDS Patient Care STDS. 2007;21:897-899.
27. Altice FL, Mezger JA, Hodges J, et al. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. Clin Infect Dis. 2004;38:S376-S387.
28. Smith-Rohrberg D, Altice FL. Randomized controlled trials of DAART for HIV+ patients: questions about study population and analytical approach. Clin Infect Dis. 2006;43:1221-1222.
29. Huba, GJ, Melchior, LA, Staff of The Measurement Group, and HRSA/ HAB's SPNS Cooperative Agreement Steering Committee (1996). Module 64: Self-Efficacy Form. Culver City, CA: The Measurement Group. Available at: http://www. themeasurementgroup.com/modules/mods/cov_mod64.htm. Accessed on April 25, 2008.
30. Marschner IC, Betensky RA, DeGruttola V, et al. Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:220-227.
31. Journot V, Chene G, Joly P, et al. Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods. Control Clin Trials. 2001;22:639-658.
32. Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2002;288:169-180.
33. Smith-Rohrberg D, Altice FL. Randomized, controlled trials of directly administered antiretroviral therapy for HIV-infected patients: questions about study population and analytical approach. Clin Infect Dis. 2006;43:1221-1222.
34. Springer S, Pesani E, Hodges J, et al. Effectiveness of antiretroviral therapy among HIV infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004;38:1754-1760.
35. Altice FL, Sullivan LE, Smith-Rohrberg D, et al. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin Infect Dis. 2006;43:S178-S183.